Caretaker injured by elephant at Delhi zoo
An official said the animal, Hira, was bothered by the mahout's behaviour.
'Indian elephants are docile by nature. Further, Hira is not in musth (a state where reproductive hormones increase in male elephants, leading to aggressive behaviour) either. There are no permanent mahouts and this can be characterised as mismanagement,' the official said.
A video of the incident was shared on social media platform X (formerly Twitter), which showed the elephant chained to a hook on the ground and three men engaging with him from a distance. Later in the video, the elephant gets aggressive and runs towards the men, while two of them flee. Hira then attacks the third man, injuring him.
'The video shows that the mahout was misbehaving, which likely agitated the elephant,' a zoo official said.
Delhi zoo director, Sanjeet Kumar, said, 'The elephant was not in musth. The contractual staff slipped and came in contact with the elephant's trunk . He has been sent to RML hospital for check-up and treatment. He has been working at the facility for six months now.'
Another zoo official, however, said that the elephant might have been in a pre-musth state.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
2 hours ago
- Hindustan Times
Session on children's blood disorder begins
Midterm PHOCON 2025 - an Indian academic platform in Pediatric Hematology and Oncology - began in Noida on Thursday with two focused pre-conference workshops at the Super Speciality Paediatric Hospital and Post Graduate Teaching Institute (SSPHPGTI), officials informed on Friday. The 2025 edition is being hosted in Noida from July 31 to August 3 (HT Photo) The 2025 edition is being hosted in Noida from July 31 to August 3, with participation from senior faculty, clinicians, nurses, and researchers from across the country and abroad. The opening day of the conference saw over 230 delegates take part in two parallel workshops - one on thalassemia care and the other on long-term hemophilia management, said officials. 'Midterm PHOCON serves as a vital platform to bridge the gap between clinical experience and emerging research in pediatric hematology and oncology. Through focused workshops and academic discussions, we aim to strengthen capacity across treatment centers in India', said organising chairperson, Midterm PHOCOM 2025, Dr Nita Radhakrishnan. Officials informed that the workshop titled 'Transfusion Matters in Thalassemia' was held in collaboration with the Thalassemia International Federation and Thalassemics India to explore crucial aspects of thalassemia care such as immunohematology, transfusion-transmitted infection screening, and the operational setup of daycare transfusion centres. 'Events like Midterm PHOCON play a key role in improving child health outcomes nationally. The conference brings together the best minds in the field, and I urge all delegates to take full advantage of this opportunity', said director SSPHPGTI, Noida, Prof AK Singh. The event also consisted of live demonstration of ThalTrack, a data management and hemovigilance software developed at SSPHPGTI, which aims to support safer transfusion practices. The workshop was coordinated by Dr Seema Dua, Dr Satyam Arora, Dr Pokhrel, and Dr Zaibaish Khan, officials said. Running alongside, the second workshop, titled 'From Bleeds to Balance – Multidisciplinary Strategies in Long-Term Hemophilia Management', focused on holistic approaches to hemophilia care. Sessions emphasised the integration of physical therapy, mental health support, home-based care, and newer therapies. Attendees also participated in hands-on joint assessments and rehabilitation techniques. The workshop was coordinated by Dr Archit Pandharipande and senior nurse Priyanshi Tyagi. The workshops laid a strong foundation for the upcoming scientific sessions, which will be held over the next two days at SSPHPGTI Noida and Radisson Blu, Noida.
Mint
3 hours ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
Time of India
3 hours ago
- Time of India
Dieticians back traditional Indian foods for lactating mothers, but with a scientific twist
Nagpur: Clinical dieticians and doctors trained in modern medicine are now advocating the use of traditional Indian postnatal foods like 'gond laddoos', and dry fruits to support lactation, but with necessary modifications rooted in science. Tired of too many ads? go ad free now Speaking during World Breastfeeding Week (August 1–7), the Indian Dietetic Association (IDA), Nagpur Chapter and NetProFan, Nagpur Chapter, jointly emphasised that traditional foods, long trusted by Indian households, can still be effective in boosting milk production if consumed in a modern, balanced form. "Traditional Indian postnatal diets were rich in ghee and sugar, aimed at restoring strength and enhancing lactation. But given current issues like postpartum weight gain, gestational diabetes, and anaemia, we need to update these recipes for today's mothers," said Dr Renuka Mainde, convener of NetProFan, Nagpur Chapter. "Instead of consuming heavy ghee-laden laddoos, we now recommend powdered versions of the same ingredients — like gond, nuts, and seeds — with milk or porridge. This maintains nutritional value without adding health risks," she said. Dr Kavita Bakshi, convener of IDA, Nagpur Chapter, added, "Some mothers struggle to produce enough milk due to poor nutrition. Foods like oats, almonds, flaxseeds, fennel, papaya, and leafy greens — rich in B-vitamins, iron, and healthy fats — are natural galactagogues. But all of this should be part of a balanced diet, and not a replacement for proper medical advice." Dr Kavita Gupta, secretary of IDA, Nagpur Chapter, explained how breastfeeding benefits extend to both mother and child. Tired of too many ads? go ad free now "It improves glucose tolerance, reduces risk of diabetes and breast cancer, and lowers high blood pressure in women with hyperglycemia in pregnancy. The longer the duration, the better the benefit," Gupta said. She also cautioned lactating women with diabetes to consult doctors before taking any medicines. "Insulin remains the safest, but Metformin and Glipizide are also considered safe in breastfeeding as they do not significantly pass into breast milk," Gupta said. Chanchal Sahani, joint secretary, IDA, Nagpur, pointed out the added value of breast milk in building a baby's immunity, brain development, and emotional bonding while being eco-friendly and cost-effective. "Breastfeeding is a skill. Proper latch and positioning not only help the baby feed better but also prevent problems like nipple pain, engorgement, and low supply," said Shalini Kotamkar, Life Member of IDA. BOX DIETICIANS SUGGEST * Gond laddoos should be consumed in powdered form with milk or porridge instead of heavy ghee-rich pieces * Use unsaturated fats from nuts and seeds instead of excess ghee * Include iron-rich leafy vegetables, pulses, and whole grains to combat anaemia * Avoid fried snacks with trans fats that delay postnatal recovery * Balance sugar intake in traditional sweets to prevent postpartum weight gain and blood sugar spikes
